Intuitive Surgical (ISRG), the leader in the robotics surgery device market, has seen tremendous growth over the last few quarters, driven by innovative technologies and a strong market position and business model. For a company overview, be sure to read Your Guide to Intuitive Surgical: Robotic Surgical Systems Leader.
In this part of the series, we’ll look at Wall Street’s recommendations and target prices for ISRG stock over the next 12 months. According to the latest rating recommendations in a Reuters survey comprised of 18 brokerage companies, 61.0% of the firms gave ISRG a “buy” rating, and 33.0% rated it a “hold.” One analyst gave the stock a “sell” rating.
In the above chart, you can see a recommendation summary for Intuitive Surgical over the next 12 months. As of October 5, 2017, the stock’s consensus 12-month target price is $1,016.20. The consensus target price amounts to a 12-month return potential of -6.3% on the stock’s closing price of $1,084.90 on October 4, 2017.
Peers TransEnterix (TRXC), Medtronic (MDT), and Stryker (SYK) have average broker target prices of $3.58, $91.10, and $152.05, respectively. These targets represent 12-month stock returns of 131.0%, 14.6%, and 2.5%, respectively, as of October 5, 2017.
Latest recommendation updates
On October 2, 2017, RBC Capital reaffirmed its “hold” rating on ISRG stock. It has a price target of $1,000 on the stock. On September 25, 2017, Wedbush reiterated its “outperform” rating on ISRG stock and gave it a target price of $1,060. Tao Levy, a Wedbush analyst, pointed to high investor expectations from the da Vinci Sp launch as one of the factors driving the stock price higher. However, Levy sees certain challenges, which investors seem to have missed.
Investors can consider the iShares Edge MSCI USA Minimum Volatility (USMV) for exposure to Intuitive Surgical. USMV invests ~1.5% of its total investments in ISRG.